Shandong Fontacea is licensed for anti-IL17A monoclonal antibody from Janssen

文章附图

Shandong Fontacea pharmaceutical Co. Ltd. ("Fontacea") announced on September 9th, 2019 that it has entered into an exclusive license, development and commercialization agreement with Janssen Biotech, Inc., to develop and commercialize pharmaceutical products containing a human IgG1λ anti-human IL-17A neutralizing monoclonal antibody in People's Republic of China ("China") including Hong Kong SAR, Macao SAR, Taiwan and South Korea.

"Our agreement with Janssen on the development of this novel monoclonal antibody reflects our strong interest in interleukin 17A as an important therapeutic target and our confidence that it has the potential to revolutionize the treatment of several disease and significantly improve the quality of life for our patients," said Mr. Yanliang Chu, CEO and president of Fontacea. "With the commitment and resources provided by our local government and investors, I believe this will be the beginning of our discovery and development of novel medicines to help patients around the world."

Share to: